Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Byron S.A
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Curating synthetic lethality-based oncology preclinical studies Search strategy To curate the synthetic lethal pairs with an aim to treat human cancer, we first performed a PubMed literature search with the search term (("synthetic lethality"[All Fields] OR "synthetic lethal"[All Fields]) AND "cancer"[All Fields] AND "human"[All Fields] AND ("in vivo"[All Fields] OR "mouse"[All Fields])) NOT "Review"[Publication Type] in April, 2022. The search yielded 1,233 journal articles.
Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis
Highlights • The structural patterns of cfDNA are altered in the blood of patients with cancer • Xenograft models (n = 16) confirm these patterns are cancer derived • Integrating cfDNA patterns yields 72% detection at 95% specificity (n = 628) • Combining cfDNA patterns can predict shorter survival Summary The structure of cell-free DNA (cfDNA) is altered in the blood of patients with cancer.
Cell free ACE2 RNA: A potential biomarker of COVID-19 severity
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
Highlights • Pan-cancer epigenetic aberrations and their transcriptional and translational changes • FGFR2 and EGFR hypomethylation are bona fide driver DNA methylation events • STAT5A methylation is a potential switch for immunosuppression in squamous tumors • Methylation subtypes illuminate cell origin, tumor heterogeneity, and tumor phenotype Summary DNA methylation plays a critical role in establishing and maintaining cellular identity.
BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer
Highlights • FGFR4 inhibition sensitizes CRC cells to BCL-XL inhibition and spares normal cells • BCL-XL targeting BH3 mimetics induce FGF2-mediated FGFR4 pathway activation • FGFR4 activation in CRC cells can induce apoptosis resistance by upregulating MCL-1 Summary The heterogeneous therapy response observed in colorectal cancer is in part due to cancer stem cells (CSCs) that resist chemotherapeutic insults.
Genome-wide spatial expression profiling in formalin-fixed tissues
64 Tissue Preparation Guide for Visium Demonstrated Protocol CG000240 RevC 10x Genomics. from Step 1.3 onward: an isopentane bath in a liquid nitrogen bath was prepared. The organoids were submerged into the isopentane until fully frozen, then they were transferred into a cryomold previously filled with pre-chilled O.C.T. for embedding avoiding bubbles. The cryomold containing the tissue and O.C.T. was immediately placed on dry ice until frozen.
The E3 ligase TRAF4 Promotes IGF Signaling by Mediating Atypical Ubiquitination of IRS-1
Abstract Insulin-like growth factor (IGF) is a potent mitogen that activates the IGF receptor (IGFR)/insulin receptor substrate (IRS) axis, thus stimulating growth in normal cells and uncontrolled cell proliferation in cancer. Post-translational modifications of IRS such as ubiquitination tightly control IGF signaling, and we previously identified IRS-1 as a potential substrate for the E3 ubiquitin ligase TRAF4 using an unbiased screen.
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT
Highlights • CRISPR/Cas9 knockout library screening identified CDK12 linking anti-HER2 TKIs resistance. • CDK12 inhibition increased the efficacy of anti-HER2 tyrosine kinase inhibitors lapatinib. • CDK12 suppression repressed activation of PI3K/AKT signalling pathway. • HER2 + breast cancer patients with CDK12-amplification are resistant to HER2-targeted treatment.
Application of DNA- and RNA-based sequencing techniques to tumour tissue samples in the clinical laboratory
Next-generation sequencing (NGS) technologies have become an indispensable tool within the research field driving genomic discoveries and furthering our understanding of the genomic changes that lead to human disease. NGS technologies have great potential to provide invaluable genomic data that can be used to improve clinical diagnosis and the delivery of precision medicine. Over the past decade NGS has translated into the clinical setting for both hereditary and somatic indications.
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Summary The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder cancer) is poor, while the incidence of these cancers is increasing. Most patients are diagnosed with advanced disease when treatment options are limited to palliative approaches, mainly focused on chemotherapy.
A Conserved Allosteric Pathway in Tyrosine Kinase Regulation
Highlights • There is an allosteric pathway between the DFG motif and the molecular brake • An isoleucine near the DFG motif serves as a conduit of allostery • Pathological mutations at the molecular brake perturb the allosteric network • Molecular brake mutants decrease kinase thermal stability Summary An autoinhibitory network of hydrogen bonds located at the kinase hinge (referred to as the “molecular brake”) regulates the activity of several receptor tyrosine kinases.
exceRpt: A Comprehensive Analytic Platform for Extracellular RNA Profiling
Highlights • exceRpt processes and analyzes exRNA profiling data • exceRpt generates quality control metrics, RNA abundance estimates, and reports • A user-friendly, browser-based graphical interface is available • exceRpt processes all RNA-seq datasets in the exRNA Atlas Summary Small RNA sequencing has been widely adopted to study the diversity of extracellular RNAs (exRNAs) in biofluids; however, the analysis of exRNA samples can be challenging: they are vulnerable to contamination and...
Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease
Gene-panel and whole-exome analyses are now standard methodologies for mutation detection in Mendelian disease. However, the diagnostic yield achieved is at best 50%, leaving the genetic basis for disease unsolved in many individuals. New approaches are thus needed to narrow the diagnostic gap. Whole-genome sequencing is one potential strategy, but it currently has variant-interpretation challenges, particularly for non-coding changes.
RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy
Highlights Cancer immunotherapy is a promising therapeutic area with the potential to impact a larger population of patients. Clinical adoption of RNA sequencing has potential to reveal novel prognostic or predictive biomarkers and expand the number of patients who can benefit from cancer immunotherapy. Algorithmic developments in RNA data allow for unprecedented profiling of the composition, specificity, and phenotype of the tumor immune response in a single assay.
Maximizing the Utility of Cancer Transcriptomic Data
Highlights The explosive volume of cancer transcriptomic data provides opportunities to understand transcriptomic events in the genome. Advances in mining cancer transcriptomic data enable us to understand the complexity of the transcriptome. Transcriptomic events, including noncoding RNA, post-transcriptional regulation, exogenous RNA, and transcribed genetic variants, inform the discovery of novel biomarkers and therapeutic targets.
Implantable microdevices for treating brain tumors
The bigger picture Despite the billions of dollars invested in preclinical and clinical research, the survival rate for patients with brain tumors has not improved significantly over the past 45 years. This stands in stark contrast to the improvements made in treatment of other cancers over the same period. Implantable microdevices hold the potential to facilitate delivery of multiple therapeutic agents simultaneously with minimal disruption of the underlying brain parenchyma.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Byron
Contact Byron, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack